Generate Biomedicines

Company snapshot

Pioneering generative biology to create breakthrough therapeutics.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Generate Biomedicines. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Generate Biomedicines.

1. Jun 8, 2026 Clinical update

   GB-0895-101 — Phase 1

2. Jun 8, 2026 Clinical update

   0.9% sodium chloride, GB-0895 — Phase 3

3. Jun 8, 2026 Clinical update

   GB-0895 (SC) — Phase 1

4. Jun 5, 2026 Clinical update

   GB-0669 — Phase 1

5. May 23, 2026 Clinical update

   GB-0895 — Phase 3

View all clinical trial activity →

• What is Generate Biomedicines?

  Generate Biomedicines is a pharma organization headquartered in Somerville, USA. It trades on NYSE under ticker GENB. Primary therapeutic focus areas include severe uncontrolled asthma, mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma, SARS CoV-2, Sev

• Is Generate Biomedicines publicly traded?

  Yes. Generate Biomedicines is listed with ticker GENB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Generate Biomedicines develop or market?

  We link 7 drug profile(s) where Generate Biomedicines is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/generate-biomedicines#company-drugs.

• What are the latest developments for Generate Biomedicines?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Generate Biomedicines focus on?

  Generate Biomedicines focuses on severe uncontrolled asthma, mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma based on our analysis of their pipeline programs and drug development activities.